KR101405437B1 - 줄기세포 유래 미세소포를 포함하는 신경 생성 촉진용 조성물 - Google Patents

줄기세포 유래 미세소포를 포함하는 신경 생성 촉진용 조성물 Download PDF

Info

Publication number
KR101405437B1
KR101405437B1 KR1020120088778A KR20120088778A KR101405437B1 KR 101405437 B1 KR101405437 B1 KR 101405437B1 KR 1020120088778 A KR1020120088778 A KR 1020120088778A KR 20120088778 A KR20120088778 A KR 20120088778A KR 101405437 B1 KR101405437 B1 KR 101405437B1
Authority
KR
South Korea
Prior art keywords
stem cell
ischemic
cells
derived
nerve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020120088778A
Other languages
English (en)
Korean (ko)
Other versions
KR20130019356A (ko
Inventor
방오영
문경준
조연희
김석재
김동희
Original Assignee
사회복지법인 삼성생명공익재단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사회복지법인 삼성생명공익재단 filed Critical 사회복지법인 삼성생명공익재단
Priority to US14/238,798 priority Critical patent/US20150045298A1/en
Priority to EP12824443.1A priority patent/EP2745840B1/en
Priority to JP2014525931A priority patent/JP5872041B2/ja
Priority to PCT/KR2012/006478 priority patent/WO2013025042A2/ko
Publication of KR20130019356A publication Critical patent/KR20130019356A/ko
Application granted granted Critical
Publication of KR101405437B1 publication Critical patent/KR101405437B1/ko
Priority to US15/649,842 priority patent/US10406180B2/en
Assigned to (주)에스엔이바이오 reassignment (주)에스엔이바이오 권리의 전부이전등록 Assignors: 사회복지법인 삼성생명공익재단
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
KR1020120088778A 2011-08-16 2012-08-14 줄기세포 유래 미세소포를 포함하는 신경 생성 촉진용 조성물 Active KR101405437B1 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US14/238,798 US20150045298A1 (en) 2011-08-16 2012-08-14 Composition including stem cell-derived microvesicles for promoting neurogenesis
EP12824443.1A EP2745840B1 (en) 2011-08-16 2012-08-14 Composition including stem cell-derived microvesicles for use in promoting neurogenesis
JP2014525931A JP5872041B2 (ja) 2011-08-16 2012-08-14 幹細胞由来微小胞を含む神経生成促進用組成物
PCT/KR2012/006478 WO2013025042A2 (ko) 2011-08-16 2012-08-14 줄기세포 유래 미세소포를 포함하는 신경 생성 촉진용 조성물
US15/649,842 US10406180B2 (en) 2011-08-16 2017-07-14 Composition including stem cell-derived microvesicles for promoting neurogenesis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110081147 2011-08-16
KR20110081147 2011-08-16

Publications (2)

Publication Number Publication Date
KR20130019356A KR20130019356A (ko) 2013-02-26
KR101405437B1 true KR101405437B1 (ko) 2014-06-11

Family

ID=47897528

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020120088778A Active KR101405437B1 (ko) 2011-08-16 2012-08-14 줄기세포 유래 미세소포를 포함하는 신경 생성 촉진용 조성물

Country Status (5)

Country Link
US (2) US20150045298A1 (https=)
EP (1) EP2745840B1 (https=)
JP (1) JP5872041B2 (https=)
KR (1) KR101405437B1 (https=)
WO (1) WO2013025042A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201302468D0 (en) * 2013-02-12 2013-03-27 Reneuron Ltd Stem cell product
AU2013249786A1 (en) * 2012-04-16 2014-11-06 The Regents Of The University Of California Ocular therapeutics using embryonic stem cell microvesicles
KR101540698B1 (ko) * 2012-10-05 2015-07-30 사회복지법인 삼성생명공익재단 허혈혈청을 포함하는 줄기세포 활성화 촉진용 조성물 및 줄기세포의 활성화 촉진 방법
GB201317887D0 (en) 2013-10-09 2013-11-20 Reneuron Ltd Product
KR101662405B1 (ko) * 2013-12-12 2016-10-05 사회복지법인 삼성생명공익재단 줄기세포 유래 엑소좀을 유효성분으로 포함하는 뇌혈관 질환 치료용 약학적 조성물
CN105520911A (zh) * 2014-09-30 2016-04-27 重庆润泽医药有限公司 一种奥拉西坦脂质微泡及其制备方法
AU2016211671B2 (en) 2015-01-26 2022-05-26 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CA3003152A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
EP3423070B1 (en) * 2016-03-03 2022-05-04 Henry Ford Health System 3-d collagen scaffold-generated exosomes and uses thereof
EP3308795A1 (en) * 2016-10-12 2018-04-18 Unicyte EV AG A composition of extracellular vesicles (evs) and medical uses thereof
EP3568143B1 (en) * 2017-01-11 2023-12-13 Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung Mesenchymal stem cell-derived extracellular vesicles and their medical use
KR102184722B1 (ko) * 2018-01-31 2020-12-01 서울대학교산학협력단 성체줄기세포 유래의 나노베시클 및 이의 표적 치료용 용도
US20210228643A1 (en) 2018-07-26 2021-07-29 Uniwersytet Jagiellonski N vivo delivery system of the genome dna modifying enzymes and the use thereof
KR102320800B1 (ko) * 2018-10-25 2021-11-02 사회복지법인 삼성생명공익재단 효능이 증진된 줄기세포 유래 미세소포, 이의 용도 및 효능강화 방법
US11351119B2 (en) 2018-10-25 2022-06-07 Samsung Life Public Welfare Foundation Stem cell-derived microvesicles with enhanced efficacy, use thereof, and method for enhancing efficacy
CN114306238A (zh) * 2020-09-29 2022-04-12 中山大学 囊泡在制备治疗肺部疾病的药物中的应用
WO2023055222A1 (ko) * 2021-10-01 2023-04-06 주식회사 입셀 유도만능줄기세포 배양 배지 유래 성분을 포함하는 조성물 내지 이의 용도
WO2024090922A1 (ko) * 2022-10-24 2024-05-02 주식회사 디자인셀 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물
WO2025182103A1 (ja) * 2024-02-28 2025-09-04 セルソース株式会社 脳梗塞の機能予後改善用組成物
KR20260010585A (ko) * 2024-07-12 2026-01-21 (주) 테라베스트 조혈모세포 또는 자연살해세포 유래의 세포외 소포체 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100122087A (ko) * 2008-02-22 2010-11-19 에이전시 포 사이언스, 테크놀로지 앤드 리서치 중간엽 줄기세포 입자

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2617428A1 (en) * 2006-08-15 2013-07-24 Agency for Science, Technology and Research Mesenchymal stem cell conditioned medium
EP2209481B1 (en) 2007-10-15 2013-03-13 Fresenius Medical Care Deutschland GmbH Use of microvesicles (mvs) for preparing a medicament having adjuvant activity on endothelial cell transplantation, particularly in the treatment of diabetes by pancreatic islet transplantation, and related method
ES2523098T3 (es) * 2007-10-29 2014-11-20 Fresenius Medical Care Deutschland Gmbh Microvesícula (MV) derivada de células madre para su uso en la inhibición de la apoptosis inducida por un agente citostático
CA2711218C (en) * 2008-01-04 2019-08-06 Lydac Neuroscience Limited A method of producing a population of differentiated cells
WO2010070141A2 (en) * 2008-12-19 2010-06-24 Cellerix, S.A. Compositions comprising adipose stem cells
JP5667180B2 (ja) * 2009-07-01 2015-02-12 イオン メディックス インコーポレイテッド 哺乳類の有核細胞に由来するマイクロベシクル及びその用途
SG2014010698A (en) * 2009-11-02 2014-05-29 Agency Science Tech & Res Methods of monitoring cellular states

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100122087A (ko) * 2008-02-22 2010-11-19 에이전시 포 사이언스, 테크놀로지 앤드 리서치 중간엽 줄기세포 입자

Also Published As

Publication number Publication date
WO2013025042A3 (ko) 2013-06-13
JP2014524437A (ja) 2014-09-22
US20170368103A1 (en) 2017-12-28
EP2745840A4 (en) 2015-04-22
EP2745840A2 (en) 2014-06-25
EP2745840B1 (en) 2017-07-12
US10406180B2 (en) 2019-09-10
US20150045298A1 (en) 2015-02-12
KR20130019356A (ko) 2013-02-26
WO2013025042A2 (ko) 2013-02-21
JP5872041B2 (ja) 2016-03-01

Similar Documents

Publication Publication Date Title
KR101405437B1 (ko) 줄기세포 유래 미세소포를 포함하는 신경 생성 촉진용 조성물
JP7246569B2 (ja) 幹細胞由来エクソソーム生成促進及び幹細胞能増強用組成物
RU2417093C2 (ru) Очищенный компонент цианобактерий и способ применения
KR101980453B1 (ko) 줄기세포 유래 엑소좀 생성 촉진용 조성물
JP2016128521A (ja) 虚血組織の細胞療法
KR20140040696A (ko) 간엽줄기세포 및 면역조절 t 세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
Wang et al. CXCR4+ CD45− BMMNC subpopulation is superior to unfractionated BMMNCs for protection after ischemic stroke in mice
KR20190063453A (ko) 줄기세포 유래 엑소좀 생성 촉진용 조성물
JPWO2006041088A1 (ja) 脳移行性骨髄前駆細胞
JP7089283B2 (ja) 細胞製剤および細胞製剤の製造方法
CN116077531A (zh) 外泌体在制备脑卒中治疗用产品中的用途
KR20120096793A (ko) 태반 유래 줄기세포를 포함한 면역반응억제용 조성물
Kashani et al. 17β-Estradiol enhances the efficacy of adipose-derived mesenchymal stem cells on remyelination in mouse model of multiple sclerosis
KR20130012552A (ko) 줄기세포를 유효성분으로 포함하는 난청의 예방 및 치료를 위한 세포 치료제 조성물 및 이의 이식 방법
KR102130502B1 (ko) P 물질을 포함하는 줄기세포 유래 엑소좀 생성 촉진 및 줄기세포능 증가용 조성물
WO2025170054A1 (ja) 脊髄梗塞治療のための多能性幹細胞
US20210023141A1 (en) Stem cells and progenitor cells bearing cd31
JP2008063290A (ja) 間葉系に関連する細胞を含んでなる、パーキンソン病またはパーキンソン症候群のための治療薬およびこれを用いた治療方法
KR20180134679A (ko) 호밍능이 향상된 줄기세포 및 이의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20120814

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131031

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20140528

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20140602

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20140602

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20170329

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20170329

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20180329

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20180329

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20190425

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20190425

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20200326

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20210526

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20220602

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20230327

Start annual number: 10

End annual number: 10